Boehringer Ingelheim and ViraTherapeutics announce immuno-oncology alliance

Boehringer Ingelheim has announced a new partnership with ViraTherapeutics, a biopharmaceutical company specialising in the development of oncolytic virus therapies.

The long-term collaboration will focus on the joint development of a next-generation oncolytic virus therapy platform, as well as investigating ViraTherapeutics' lead candidate VSV-GP alone and in combination with other therapies.

This novel technology has been developed with joint support from lead investors EMBL Ventures and Boehringer Ingelheim Venture Fund, with ViraTherapeutics to take responsibility for preclinical and clinical testing of VSV-GP in phase I trials.

Boehringer Ingelheim has gained the right to acquire ViraTherapeutics after the conclusion of phase I clinical development of this drug. Early studies have suggested that VSV-GP is able to prime and boost anticancer immune responses without prompting effective antiviral immune responses.

Dr Michel Pairet, the member of Boehringer Ingelheim's board of managing directors responsible for innovation, said: "The new collaboration is an example of Boehringer Ingelheim's increasing focus on partnering and further complements the company's growing immuno-oncology pipeline that includes, among others, a therapeutic cancer vaccine and next-generation checkpoint inhibitors."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.